To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
8 Current news of Pevion Biotech
rss
Pevion’s therapeutic Candida vaccine generates functional B cell memory in all vaccinees
01-19-2012
Pevion Biotech AG announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion’s second generation ...
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
10-13-2011
Pevion Biotech AG announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international representative ...
Pevion appoints Didier Hoch as Chairman of the Board
02-11-2011
Pevion Biotech Ltd. announced the appointment of Didier Hoch as Chairman of its Board of Directors. Until recently, Dr Hoch was President of Sanofi-Pasteur MSD, where he played a pivotal role in launching innovative vaccines, such as Gardasil®, in Europe. Prior to his position as President of ...
Pevion´s breakthrough candida vaccine demonstrates safety and immunogenicity in Phase I clinical study
11-15-2010
Pevion Biotech AG announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. ...
Pevion Biotech appoints new CEO and secures CHF 10 Million financing
09-09-2010
Pevion Biotech AG announced the appointment of Evert Kueppers as its new Chief Executive Officer, succeeding Thomas Stauffer. Prior to joining Pevion, Evert Kueppers was CEO of Pieris AG, a Munich-based biotechnology company, which he successfully restructured and refinanced raising a total ...
Pevion Biotech and CEVEC Pharmaceuticals Sign Exclusive License Option Agreement
05-28-2010
Pharmaceuticals announced the signing of an exclusive license option agreement with Pevion Biotech. The agreement enables Pevion Biotech to exclusively use CEVEC’s transient CAP-T™ cell expression technology to manufacture and commercialize a protein antigen for vaccination against a ...
Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration
12-22-2008
Generex Biotechnology Corporation and Pevion Biotech Ltd. have signed an agreement to work together to develop next-generation vaccines and immunotherapeutic products. The initial goal of the collaboration will be to investigate synergies in the cancer vaccine approaches of the two ...
Crucell Sells Stake in Pevion Biotech
11-16-2007
Crucell N.V. announced that Berna Biotech AG, its wholly owned subsidiary, has sold all the 2.9 million shares it owned in Pevion Biotech Ltd, Bern (Switzerland) to other shareholders of Pevion Biotech. This number of shares represents 36 percent of Pevion Biotech's capital and results in net ...
Page 1 From 1
